Lack of squamous cell lung carcinoma in vitro chemosensitivity to various drug regimens in the adenosine triphosphate cell viability chemosensitivity assay

• Autorzy: Vogt U. , Striehn E. , Bosse U. , Klinke F. , Falkiewicz B.
• Języki publikacji: EN

Abstrakty

EN

A pilot study on squamous cell lung carcinoma (LC) chemosensitivity in adenosine triphosphate cell viability chemosensitivity assay (ATP-CVA) was performed. Besides the histological investigation, a modified ATP-CVA was used for the analysis of cancer cell chemosensitivity to four drug regimens, including topotecan, a promising agent for non-small-cell lung cancer (NSCLC) chemotherapy. Results of in vitro chemosensitivity testing showed chemoresistance or only weak response in the predominant amount of tumors.

Słowa kluczowe

EN

adenosine triphosphate; drug resistance; antineoplastic agent; topotecan; tumour cell; antitumour drug; lung carcinoma; cell viability; in vitro

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 1999
• Tom: 46
• Numer: 2
• Opis fizyczny: p.299-302

Twórcy

autor

Vogt U.

• European Laboratory Association, Roggenkampstr.10, 49477 Ibbenburen, Germany, e-mail: [e-mail]

autor

Striehn E.

autor

Bosse U.

autor

Klinke F.

autor

Falkiewicz B.

Bibliografia

• Andreotti, P.E., Linder, D., Hartmann, D.M., Cree, I.A., Pazzagli, M. & Bruckner, H.W. (1994) J. Biolumin. Chemilumin. 9,373-378.
• Andreotti, P.E., Cree, I.A., Kurbacher, C.M., Hart mann, D.M., Linder, D., Harel, G., Gleiber- man, I., Caruso, P.A., Ricks, S.H., Untch, M., Sartori, C. & Bruckner, H.W. (1995) Cancer Res. 55, 5276-5282.
• Cree, I.A., Kurbacher, C.M., Untch, M., Suther­land, L.A., Hunter, E.M., Subedi, A.M.C., James, E.A., Dewar, J.A., Preece, P.E., An­dreotti, P.E. & Bruckner. H.W. (1996) Anti- Cancer Drugs 7, 630-635.
• Cree, I.A. & Kurbacher, C.M. (1997) Anti-Cancer Drugs 8, 541-548.
• De Vita, V.T., Jr. (1997) in Cancer: Principles and Practice of Oncology (De Vita, V.T., Jr., Hell- man, S. & Rosenberg, S.A., eds.) pp. 333-347, Lippincott-Raven Publishers, Philadelphia.
• Hunter, E.M., Sutherland, L.A., Cree, I.A., Su­bedi, A.M.C., Hartmann, D.M., Linder, D. & Andreotti, P.E. (1994) Anti-Cancer Drugs 5, 171-176.
• Köchli, O.R., Sevin, B.-U., Averette, H.E. & Hal­ler, U. (1994a) Contńb. Gynecol. Obstet. 19, 12-23.
• Köchli, O.R., Perras, J.P. & Sevin, B.-U. (1994b) Contńb. Gynecol. Obstet. 19, 108-121.
• Köchli, O.R., Sevin, B.U., Perras, J.P., Angioli, R., Steren, A., Rodriguez, M., Ganjei, P. & Aver­ette, H.E. (1994c) Oncology 51, 35-41.
• Kurbacher, C.M., Cree, I.A., Bruckner, H.W., Brenne, U., Kurbacher, J.A., Mueller, K., Ack­ermann, T., Gilster, T.J., Wilhelm, L.M., Engel, H., Mallmann, P.K. & Andreotti, P.E. (1998) Anticancer Drugs 9, 51-57.
• Lilenbaum, R.C., Langenberg, P. & Dickersin, K. (1998) Cancer 82, 116-126.
• Mountain, C.F. (1997) Chest 111, 1710-1717.
• Vogt, U., Falkiewicz, B., Striehn, E., Bosse, U. & Klinke. F. (1998) Diagn. Lab. 34 (Suppl. 1), 57 Abstract.
• Zabel, M., Kaczmarek, A., Lukianow, R., Ramlau, R. & Górny, A. (1992) Nowotwory 42, 187-192 (in Polish).
• Zabel, M., Kaczmarek, A., Rozmiarek, A. & Mar­kowska, J. (1997) Współczesna Onkologia 2, 17-19 (in Polish).